Apyx Medical Co. (NASDAQ:APYX) Short Interest Update

Apyx Medical Co. (NASDAQ:APYXGet Rating) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 489,200 shares, a drop of 19.3% from the August 15th total of 606,100 shares. Based on an average trading volume of 258,800 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.6% of the shares of the company are short sold.

Apyx Medical Price Performance

Apyx Medical stock opened at $5.65 on Friday. The stock has a market capitalization of $195.32 million, a PE ratio of -11.08 and a beta of 1.51. Apyx Medical has a 12 month low of $3.01 and a 12 month high of $17.50. The business has a 50 day simple moving average of $7.67 and a 200-day simple moving average of $6.49.

Apyx Medical (NASDAQ:APYXGet Rating) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. The business had revenue of $10.29 million during the quarter, compared to analysts’ expectations of $10.66 million. Apyx Medical had a negative return on equity of 34.39% and a negative net margin of 34.21%. During the same period in the previous year, the business earned ($0.12) earnings per share. On average, equities research analysts anticipate that Apyx Medical will post -0.52 EPS for the current fiscal year.

Insider Activity at Apyx Medical

In related news, CEO Charles D. Goodwin II purchased 11,750 shares of Apyx Medical stock in a transaction that occurred on Monday, August 29th. The stock was bought at an average cost of $5.96 per share, for a total transaction of $70,030.00. Following the completion of the transaction, the chief executive officer now owns 40,000 shares in the company, valued at $238,400. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 11.60% of the stock is owned by company insiders.

Institutional Trading of Apyx Medical

A number of institutional investors have recently made changes to their positions in APYX. Raymond James & Associates acquired a new stake in shares of Apyx Medical in the fourth quarter worth approximately $196,000. Dimensional Fund Advisors LP boosted its stake in shares of Apyx Medical by 0.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 527,107 shares of the company’s stock worth $6,757,000 after acquiring an additional 2,446 shares during the last quarter. Invenire Partners LP acquired a new stake in shares of Apyx Medical in the fourth quarter worth approximately $4,461,000. Perkins Capital Management Inc. acquired a new stake in shares of Apyx Medical in the first quarter worth approximately $67,000. Finally, Signaturefd LLC acquired a new stake in shares of Apyx Medical in the first quarter worth approximately $344,000. 60.85% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on APYX. Piper Sandler lifted their price target on Apyx Medical from $6.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, August 12th. Lake Street Capital boosted their price objective on Apyx Medical from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, July 19th.

Apyx Medical Company Profile

(Get Rating)

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.

Recommended Stories

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.